Mark Schoenebaum, the biotech analyst at ISI Group, wrote in a note to clients that Celgene presented data on an investor call that shows that by selecting out certain types of patients, doctors might be able to screen out patients at highest risk of second cancers, particularly lymphomas.
FORBES: Celgene Stock Falls On Worries About Secondary Cancers